Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Biopharmaceutical company developing plant-derived recombinant proteins and immunocytotherapeutic drugs using rice-based technology.
Heyuan Biotechnology, based in Beijing, China, with an additional base in Tianjin, develops innovative biopharmaceuticals by leveraging "rice-based hematopoiesis" technology to produce high-purity recombinant human serum albumin and other proteins from genetically modified rice cells. This innovative approach aims to overcome limitations of traditional plasma-derived products, effectively transforming agricultural production into a sustainable source for pharmaceutical ingredients. Beyond recombinant proteins, the company also focuses on immunocytotherapeutic drugs, building an integrated industrial chain encompassing research, development, and sales. In July 2025, its core product, HY1001 (Aofumin Recombinant Human Albumin Injection), received marketing approval as China's first plant-derived recombinant human albumin drug. Heyuan Liji, a joint venture with Shanghai Liji Biotechnology, was established in 2023 to further expand its operations. The company is led by CEO Lulu Lu and was founded in 2006 by Professor Yang Daichang.
Heyuan Biotechnology has raised $44.2M across 1 funding round.
Heyuan Biotechnology has raised $44.2M in total across 1 funding round.
Heyuan Biotechnology has raised $44.2M in total across 1 funding round.
Heyuan Biotechnology's investors include Loyal Valley Capital, GP Capital, Morningside, Sherpa Healthcare Partners.
Heyuan Biotechnology has raised $44.2M across 1 funding round. Most recently, it raised $44.2M Series C in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 23, 2020 | $44.2M Series C | Loyal Valley Capital | GP Capital, Morningside, Sherpa Healthcare Partners | Announced |